MLV & Co. Initiates Intercept Pharmaceuticals With Hold
Analysts at MLV & Co. initiated coverage on Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) with a Hold rating, according to sources.
The target price for Intercept Pharmaceuticals is set to $273.
Intercept Pharmaceuticals shares have dropped 32.30% over the past 52 weeks, while the S&P 500 index has surged 11.16% in the same period.
Intercept Pharmaceuticals' shares fell 3.22% to $285.01 in pre-market trading.
Latest Ratings for ICPT
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Canaccord Genuity | Maintains | Hold | |
Mar 2022 | RBC Capital | Maintains | Sector Perform | |
Mar 2022 | Needham | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: MLV & Co.Initiation Analyst Ratings